EVO News and Press, Evotec SE From 09/21/22

Evotec ( NASDAQ: EVO ) ( OTCPK:EVOTF ) is collaborating with Adapsyn Bioscience to gain access to novel drug-like small molecules from microorganisms. Financial details were not disclosed. Under the agreement, Evotec will have the opportunity to evalu...

Evotec ( NASDAQ: EVO ) ( OTCPK:EVOTF ) said the U.S. Department of Defense (DOD) awarded it a contract worth up to $49.9M for the rapid development of monoclonal antibody (mAb)-based drug product prototypes targeting plague. Under the agreement, Evotec's Seattle-ba...

JUST - EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS ANTI-PLAGUE MABS EVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICES HAMBURG, GERMANT / ACCESSWIRE / September 20, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDA...

J.POD ® TOULOUSE, FRANCE (EU) BRINGS A DISRUPTIVE, FLEXIBLY SCALABLE BIOLOGICS MANUFACTURING TECHNOLOGY TO THE REGION THE MANUFACTURING FACILITY IS EXPECTED TO BE OPERATIONAL IN H2 2024 HAMBURG, GERMANY / ACCESSWIRE / September 16, 2-022 / Evotec SE (Frankfurt Stock Exchan...

LONDON, Ontario, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/ XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that it has completed the second and final tranche of its previously announced private ...

Evotec ( NASDAQ: EVO ) ( OTCPK:EVOTF ) is acquiring Central Glass Germany from Japanese chemical manufacturing company Central Glass Co. to expands its clinical and commercial manufacturing platform for small molecule therapeutics. Germany-based Evotec sa...

EXPANSION OF CGMP DRUG SUBSTANCE MANUFACTURING PLATFORM WILL CREATE A CLEAR PATH TO THE MARKET FOR RARE DISEASES AND PRECISION THERAPEUTICS EVOTEC GAINS A FULLY OPERATIONAL EU GMP CERTIFIED FACILITY IN HALLE/WESTPHALIA ALONG WITH A HIGHLY SKILLED TEAM OF APPROX. 60 CHEMISTS HAMBUR...

Evotec SE (EVOTF) Q2 2022 Earnings Conference Call August 11, 2022, 8:00 AM ET Company Participants Dr. Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operati...

The following slide deck was published by Evotec SE in conjunction with their 2022 Q2 earnings call. For further details see: Evotec SE 2022 Q2 - Results - Earnings Call Presentation

Evotec SE press release ( NASDAQ: EVO ): 1H Revenue of €336.9M (+24.2% Y/Y). Reported adjusted Group EBITDA totalled €33.6 m (H1 2021: €36.2 m); excellent Group gross margin increasing by 270 bps to 27.3%. Outlook for FY2022 redefine and mid...